Search | Clinical Trials Finder

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 40
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 32 more

Conditions: Metabolic Dysfunction Associated Steatohepatitis
Interventions: Survodutide, Placebo matching survodutide; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 126
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more

Conditions: Chronic Hepatitis C Virus (HCV) Infection Genotype 1
Interventions: ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 48
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 40 more

Conditions: Hepatic Impairment, Cirrhosis
Interventions: VIR-2218, VIR-3434; Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Rialto, California • Tustin, California • Hollywood, Florida + 2 more

Conditions: Nonalcoholic Steatohepatitis
Interventions: SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 883 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 128
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 93 more

Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 165
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 139 more

Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
Interventions: Seladelpar; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 11
States / cities: Chandler, Arizona • Sacramento, California • Aurora, Colorado + 7 more

Conditions: Liver Diseases, Hypertension, Portal
Interventions: Avenciguat, Empagliflozin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: BIO89-100; Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Hepatitis C
Interventions: Daclatasvir, Asunaprevir, BMS-791325, Ribavirin, Placebo matching Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 26
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 22 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 22 more

Conditions: Hepatitis C Virus Infection
Interventions: Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 8
States / cities: Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more

Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: Miricorilant; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Nonalcoholic Steatohepatitis
Interventions: Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA, PTM CILO/FIR; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 175
States / cities: Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more

Conditions: Liver Fibrosis, Hepatic Cirrhosis
Interventions: AZD2389; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Chandler, Arizona • Rialto, California • Atlanta, Georgia + 3 more

Conditions: Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
Interventions: BMS-986036, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 85
States / cities: Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more

Conditions: Liver Fibrosis Due to NASH
Interventions: Placebo, SIM; Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Phoenix, Arizona • Coronado, California • San Diego, California + 35 more

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: La Jolla, California • Pasadena, California • Tampa, Florida + 7 more

Conditions: Non-alcoholic Steatohepatitis
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 24
States / cities: Chandler, Arizona • Peoria, Arizona • Coronado, California + 21 more

Conditions: Hepatitis C, Chronic
Interventions: RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 15
States / cities: Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: EFX, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 46
States / cities: Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 38 more

Conditions: Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
Interventions: BI 770371, Placebo for BI 770371; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Chandler, Arizona • Coronado, California • Montclair, California + 8 more

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Lancaster, California + 38 more

Conditions: Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions: aldafermin, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 31
States / cities: Glendale, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 22 more

Search by objective public record fields.

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

Evaluating the Pharmacokinetics and Safety of Miricorilant

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)